Category: Headlines in Dermatology

Upadacitinib (Rinvoq, AbbVie) in Vitiligo: What Does the Phase 2 Data Show?

Upadacitinib (Rinvoq, AbbVie) improves Type 1 inflammation markers and circulating melanocyte-associated proteins in vitiligo.